Ultimately, this work will examine whether the treatment of TP53‐mutated AML can truly be transformed, or if, as in Pandora's box, the hope for a cure will remain elusive, constrained by the inherent complexities of this aggressive disease. This evidence concerns the gene TP53 and acute myeloid leukemia.